Completing a Yellow Card report following an adverse reaction

2014 ◽  
Vol 3 (Sup8) ◽  
pp. S28-S34
Author(s):  
Rachel Goddard
Author(s):  
J. Bart Classen

Many have argued that SARS-CoV-2 spike protein and its mRNA sequence, found in all COVID-19 vaccines, are priongenic. The UK’s Yellow Card database of COVID-19 vaccine adverse event reports was evaluated for signals consistent with a pending epidemic of COVID vaccine induced prion disease. Adverse event reaction rates from AstraZeneca’s vaccine were compared to adverse event rates for Pfizer’s COVID vaccines. The vaccines employ different technologies allowing for potential differences in adverse event rates but allowing each to serve as a control group for the other. The analysis showed a highly statistically significant and clinically relevant (2.6-fold) increase in Parkinson’s disease, a prion disease, in the AstraZeneca adverse reaction reports compared to the Pfizer vaccine adverse reaction reports (p= 0.000024). These results are consistent with monkey toxicity studies showing infection with SARS-CoV-2 results in Lewy Body formation. The findings suggest that regulatory approval, even under an emergency use authorization, for COVID vaccines was premature and that widespread use should be halted until full long term safety studies evaluating prion toxicity has een complete. Alternative vaccines like the Measles Mumps Rubella (MMR) vaccine should be explored for those desiring immunization against COVID-19.Many have argued that SARS-CoV-2 spike protein and its mRNA sequence, found in all COVID-19 vaccines, are priongenic. The UK’s Yellow Card database of COVID-19 vaccine adverse event reports was evaluated for signals consistent with a pending epidemic of COVID vaccine induced prion disease. Adverse event reaction rates from AstraZeneca’s vaccine were compared to adverse event rates for Pfizer’s COVID vaccines. The vaccines employ different technologies allowing for potential differences in adverse event rates but allowing each to serve as a control group for the other. The analysis showed a highly statistically significant and clinically relevant (2.6-fold) increase in Parkinson’s disease, a prion disease, in the AstraZeneca adverse reaction reports compared to the Pfizer vaccine adverse reaction reports (p= 0.000024). These results are consistent with monkey toxicity studies showing infection with SARS-CoV-2 results in Lewy Body formation. The findings suggest that regulatory approval, even under an emergency use authorization, for COVID vaccines was premature and that widespread use should be halted until full long term safety studies evaluating prion toxicity has been complete. Alternative vaccines like the Measles Mumps Rubella (MMR) vaccine should be explored for those desiring immunization against COVID-19.


1984 ◽  
Vol 3 (4) ◽  
pp. 261-269 ◽  
Author(s):  
I. Crombie

The number of cases of an adverse reaction which could be seen by individual doctors was investigated taking realistic values for the frequency of drug prescribing and a range of frequencies of adverse drug reactions. The results indicated that, for almost all drugs, general practitioners (GPs) will seldom see other than single cases of an adverse reaction. It is argued that doctors will be unlikely to recognize an adverse reaction from a single case (unless it presented with some striking clinical features) so that potential new adverse reactions will rarely be reported by GPs under the Yellow Card scheme. A similar analysis for hospital doctors indicated that clinicians working in some specialities, may have a greater chance of seeing more than one case of an adverse reaction. A review of the identification of several important adverse reactions revealed that all the reports from British doctors were submitted by clinicians with hospital appointments. This study suggests that the major part of the operation of the Yellow Card system will contribute little to the identification of adverse reactions and that its organization and activities need to be reassessed. A modified system designed to encourage reporting by hospital clinicians could be of greater value.


2015 ◽  
Vol 21 ◽  
pp. 38-39
Author(s):  
Issac Sachmechi ◽  
Raya Galibov ◽  
Venkat Dirish Arukala

Sign in / Sign up

Export Citation Format

Share Document